Aarhus University Seal / Aarhus Universitets segl

news item

PAPER: Selective delivery of doxorubicin to EGFR+ cancer cells by Cetuximab-DNA conjugates

Delivery of the anticancer drug Cetuximab to EGFR+ cancer cells has recently been reported in ChemBioChem.

Screenshot from the article "Selective delivery of doxorubicin to EGFR+ cancer cells by Cetuximab-DNA conjugates" published in ChemBioChem

The anticancer drug doxorubicin has low selectivity towards cancer cells. However, using the EGFR tageting antibody Cetuximab conjugated to ssDNA, doxorubicin delivery to EGFR+ cancer cells is achieved when the drug non-covalently intercalates to the DNA.

Read the full article "Selective delivery of doxorubicin to EGFR+ cancer cells by Cetuximab-DNA conjugates" at the ChemBioChem website.